Eye Care

Latest News


CME Content


Topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP), found that the study did not meet its primary endpoint of demonstrating a statistically significant improvement in the proportion of treated study eyes.

Brolucizumab is the most clinically advanced humanized single-chain antibody fragment. This type of antibody is highly sought after due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.

Stephanie Conway, PharmD, RPh, Associate Professor at Massachusetts College of Pharmacy & Health Sciences—Worcester, discusses the links between ophthalmic conditions, over-the-counter ophthalmic products, and pharmacists.

Kaelen C. Dunican, PharmD, Professor at MCPHS University—Worcester/Manchester, MA discusses an interprofessional, educational activity with pharmacy and optometry students for reviewing common, self-treatable ophthalmic conditions.